388 related articles for article (PubMed ID: 19929853)
1. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.
Ovens MJ; Davies AJ; Wilson MC; Murray CM; Halestrap AP
Biochem J; 2010 Jan; 425(3):523-30. PubMed ID: 19929853
[TBL] [Abstract][Full Text] [Related]
2. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity.
Nancolas B; Sessions RB; Halestrap AP
Biochem J; 2015 Feb; 466(1):177-88. PubMed ID: 25437897
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein.
Ovens MJ; Manoharan C; Wilson MC; Murray CM; Halestrap AP
Biochem J; 2010 Oct; 431(2):217-25. PubMed ID: 20695846
[TBL] [Abstract][Full Text] [Related]
4. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.
Guan X; Bryniarski MA; Morris ME
AAPS J; 2018 Nov; 21(1):3. PubMed ID: 30397860
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: Feeding Warburg's sweet tooth and blocking acid export as an anticancer strategy.
Pivovarova AI; MacGregor GG
Biomed Pharmacother; 2018 Feb; 98():173-179. PubMed ID: 29253765
[TBL] [Abstract][Full Text] [Related]
7. Treatment of
Follman KE; Morris ME
J Pharmacol Exp Ther; 2019 Jul; 370(1):84-91. PubMed ID: 31010842
[TBL] [Abstract][Full Text] [Related]
8. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
9.
Rodriguez-Cruz V; Morris ME
J Pharmacol Exp Ther; 2021 Jul; 378(1):42-50. PubMed ID: 33963018
[TBL] [Abstract][Full Text] [Related]
10. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
11. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70).
Wilson MC; Meredith D; Fox JE; Manoharan C; Davies AJ; Halestrap AP
J Biol Chem; 2005 Jul; 280(29):27213-21. PubMed ID: 15917240
[TBL] [Abstract][Full Text] [Related]
12. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.
Hanson DJ; Nakamura S; Amachi R; Hiasa M; Oda A; Tsuji D; Itoh K; Harada T; Horikawa K; Teramachi J; Miki H; Matsumoto T; Abe M
Oncotarget; 2015 Oct; 6(32):33568-86. PubMed ID: 26384349
[TBL] [Abstract][Full Text] [Related]
13. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
Lee JY; Lee I; Chang WJ; Ahn SM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Cho JH; Kim SY; Kim KM; Lee S; Kim ST; Park SH; Lee J; Park JO; Park YS; Lim HY; Kang WK
Oncotarget; 2016 Jul; 7(28):43492-43503. PubMed ID: 27224918
[TBL] [Abstract][Full Text] [Related]
14. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
[TBL] [Abstract][Full Text] [Related]
15. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle.
Wilson MC; Meredith D; Bunnun C; Sessions RB; Halestrap AP
J Biol Chem; 2009 Jul; 284(30):20011-21. PubMed ID: 19473976
[TBL] [Abstract][Full Text] [Related]
16. The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity.
Manoharan C; Wilson MC; Sessions RB; Halestrap AP
Mol Membr Biol; 2006; 23(6):486-98. PubMed ID: 17127621
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
18. A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.
Vijay N; Morse BL; Morris ME
Pharm Res; 2015 Jun; 32(6):1894-906. PubMed ID: 25480120
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.
Lamb R; Harrison H; Hulit J; Smith DL; Lisanti MP; Sotgia F
Oncotarget; 2014 Nov; 5(22):11029-37. PubMed ID: 25415228
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the binding moiety mediating the interaction between monocarboxylate transporters and carbonic anhydrase II.
Noor SI; Dietz S; Heidtmann H; Boone CD; McKenna R; Deitmer JW; Becker HM
J Biol Chem; 2015 Feb; 290(7):4476-86. PubMed ID: 25561737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
